A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.

Abstract

We carried out a four-week double-blind placebo-controlled study comparing remoxipride (n = 20) to chlorpromazine (n = 21) and placebo (n = 21) in the treatment of newly admitted schizophrenic patients with acute exacerbation. Chlorpromazine was found to be significantly better than remoxipride on the dropout rate due to inefficacy, Clinical Global… (More)

Topics

  • Presentations referencing similar topics